Results: 2

1.

Figure. From: Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children.

Figure 1. Participant flow. ACWY_T, toddlers vaccinated with MenACWY-TT at 12–14 mo of age; MenCCRM, toddlers vaccinated with MenC-CRM197 at 12–14 mo of age; ACWY_C, children vaccinated with MenACWY-TT at 3–5 y of age; MenPS, children vaccinated with MenPS at 3–5 y of age; ATP, according to protocol; TVC, total vaccinated cohort; N, number of participants. 1Several formulations were evaluated in the primary study, but participants who received the selected formulation for further development or control vaccine were eligible to participate in the persistence study. Participants who withdrew from the primary phase were described in the previous publication. 6

Markus Knuf, et al. Hum Vaccin Immunother. 2012 July 1;8(7):866-872.
2.

Figure. From: Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children.

Figure 2. Geometric mean titers for rSBA at pre-vaccination, at 1 mo 1 and 15 mo 1 after primary vaccination (ATP cohort for persistence) and at 1 mo after the polysaccharide challenge (ATP cohort for immune memory). Notes: ATP, according to protocol; ACWY_T, toddlers primed with MenACWY-TT at 12–14 mo of age; MenCCRM, toddlers primed with MenC-CRM197 at 12–14 mo of age; ACWY_C, children primed with MenACWY-TT at 3–5 y of age; MenPS, children primed with MenPS at 3–5 y of age; Errors bars, exact 95% confidence interval; Month 0, pre-primary vaccination; Month 1, 1 mo post-primary vaccination; Month 15, 15 mo post-primary vaccination; Month 16, one month post-polysaccharide challenge. 1These numbers are not the same as those presented in the previous publication at the same timepoints because the analyses for the present study were conducted on the ATP cohorts for persistence and immune memory (Month 15) and in the previous publication the analyses were performed on the ATP cohort for immunogenicity (Month 1). *Statistically significantly higher values compared with the control group (exploratory analysis)

Markus Knuf, et al. Hum Vaccin Immunother. 2012 July 1;8(7):866-872.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk